Skip to main content

This website is intended exclusively for healthcare professionals residing and/or working in the UAE.

  1. Article
  2. Source: Campus Sanofi
  3. 16 Jul 2025

Discover the science behind Tolebrutinib: a BTK inhibitor designed to slow MS disability progression by modulating adaptive and innate immunity

Author: Sanofi

Editorial Team

   

MAT-BH-2500365-V1-June 2025  

Related

Privacy Notice Update | We have updated our Privacy Notice for Healthcare Professionals to improve your experience collaborating with us, maintain high standards of privacy and ultimately strengthen the trust you place in us. Key improvements include enhanced clarity on why and how Sanofi processes your personal data.
SitemapLegal noticePrivacy PolicyCookie PolicyContactAccessibility statement

© Sanofi 2004-2026 - All rights reserved

MAT-AE-2100444/V8/JUL2025

Privacy Notice Update | We have updated our Privacy Notice for Healthcare Professionals to improve your experience collaborating with us, maintain high standards of privacy and ultimately strengthen the trust you place in us. Key improvements include enhanced clarity on why and how Sanofi processes your personal data.
SitemapLegal noticePrivacy PolicyCookie PolicyContactAccessibility statement

© Sanofi 2004-2026 - All rights reserved

MAT-AE-2100444/V8/JUL2025